Insulin icodec: evolution or revolution in diabetes therapy?

Lancet Diabetes Endocrinol. 2023 Jun;11(6):379-380. doi: 10.1016/S2213-8587(23)00125-0. Epub 2023 May 4.

Authors

Srikanth Bellary¹, Anthony H Barnett²

Affiliations

¹ College of Health and Life Sciences, Aston University, Birmingham B4 7ET, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: s.bellary@aston.ac.uk.
² Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

PMID: 37150185
DOI: 10.1016/S2213-8587(23)00125-0

No abstract available

Publication types

Comment

MeSH terms

Diabetes Mellitus* / drug therapy
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Insulin / therapeutic use
Insulin, Long-Acting

Substances

insulin icodec
Insulin, Long-Acting
Insulin
Hypoglycemic Agents